Stockreport

TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities

TScan Therapeutics, Inc.  (TCRX) 
PDF Over 40 solid tumor patients have completed all biomarker testing in the screening protocol; ~60% of these patients qualify for at least one TCR-T in the ImmunoBank and [Read more]